I learned yesterday VELCADE is being highlighted in five presentations at the newly established, exclusive Trials in Progress session. This session will highlight a number of different abstracts.
“Data being presented at this year’s ASCO further demonstrate the effectiveness of VELCADE as a backbone of therapy in a range of multiple myeloma patient populations and treatment settings,” said Nancy Simonian, M.D., Millennium’s Chief Medical Officer.
Here is an outline about what to expect:
Bortezomib, melphalan, prednisone and thalidomide (VMPT) followed by maintenance with bortezomib and dexamethasone (VD) for initial treatment of elderly multiple myeloma patients
Presenter: Mario Boccadoro, M.D., University of Torino and Italian Multiple Myeloma Study Group, Torino, Italy
Abstract #8013: Oral presentation session: Sunday, June 6, 9:30 am CT
Lenalidomide, bortezomib, dexamethasone in patients with newly diagnosed multiple myeloma (MM): final results of a multicenter Phase I/II study
Presenter: Kenneth Anderson, M.D., Dana-Farber Cancer Institute, Boston, MA
Abstract #8016: Oral presentation session: Sunday, June 6, 10:30 a.m. CT
Reduced-dose bortezomib plus thalidomide (vTD) is superior to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): results of IFM2007-02 study
Presenter: Philippe Moreau, M.D., Hôpital de Nantes, Nantes, France
Abstract #8014: Oral presentation session: Sunday, June 6, 9:45 am CT
Weekly and twice-weekly bortezomib in AL amyloidosis: results of a phase 2 study
Presenter: Donna Reece, M.D., FRCPC, Princess Margaret Hospital, Toronto, Canada
Abstract #8023: Poster discussion session: Friday, June 4, 2:00 pm CT
No bombshells here–just more, solid results from one of the most proven and successful multiple myeloma drugs–Velcade. I am interested to hear more about the amyloidosis study. “Amy” is a disorder shared by many multiple myeloma patients.
I am incuding additional Velcade study information against solid tumors on our http://www.helpwithcancer.org/ site later today.
One additional note. Buried near the end of the “curtain raiser” press release from Millennium, I found the following statement:
Additional presentations at ASCO will include the presentation of first clinical data for several investigational molecules from the Company’s robust oncology pipeline. MLN9708 is the first oral proteasome inhibitor to enter clinical trials and is based on the Company’s groundbreaking research in protein homeostasis.
No splash, no bold print (I added that!) This is a huge deal! With Onyx’s new proteasome inhibitor, a direct competitor of Millennium’s Velcade, coming to market soon, MLN9708 should be one of the major stories at ASCO. Both from a patient and business standpoint, an “oral Velcade” could really help change the myeloma chemotherapy landscape.
So I have to wonder: Why not more pomp and circumstance about this study? True, it is only Stage I data. Still… Isn’t it going as planned? Have they hit a snag? I will see what I can find out.
Feel good and keep smiling! Pat